Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02223520 · ClinicalTrials.gov registry record · NA
Treating Parents to Reduce NICU Transmission of Staphylococcus Aureus Trial
A NA study of Staph Aureus Colonization and Staph Aureus Infection, sponsored by Johns Hopkins University.
- Completed
- Registry status
- NA
- Development phase
- 307
- Enrollment target
- 2
- Study locations
NCT02223520: Completed NA study of Staph Aureus Colonization and Staph Aureus Infection, sponsored by Johns Hopkins University.
NCT02223520 is a NA study of Staph Aureus Colonization and Staph Aureus Infection that has completed, run by Johns Hopkins University. The registered enrollment target is 307 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02223520, a NA study of Staph Aureus Colonization and Staph Aureus Infection, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- NA
- Development phase
- 307 participants
- Enrollment target
- 2
- Study locations
Study Summary
This trial will test the hypothesis that treating parents of neonates requiring NICU care with intranasal mupirocin and topical chlorhexidine bathing will reduce the spread of S. aureus from parents to neonates.
Primary Outcome
Primary outcome is neonatal acquisition of S. aureus strain that is concordant to parental S. aureus strain as determined by periodic surveillance cultures or a culture collected during routine clinical care that grows S. aureus. Survival analysis techniques will be used to compare the hazard of concordant colonization comparing Treatment and Control Groups.
Conditions Studied
Interventions
- DRUG Mupirocin and Chlorhexidine
- DRUG Placebo ointment and placebo cloths
Study Locations (2)
Maryland
- Johns Hopkins Bayview Medical Center - Baltimore
- Johns Hopkins Hospital - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 307 participants |
| Start Date | 2014-11 |
| Est. Completion | 2019-10-31 |
| Phase | NA |
What the finished NCT02223520 record still lists
NCT02223520 is an interventional study that assigns participants to a tested intervention. The registered 307 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (78% lower).
The record links to 2 conditions, with Staph Aureus Colonization appearing as the primary indexed condition, and to 2 interventions - of which Mupirocin and Chlorhexidine is the first listed.
NCT02223520 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02223520 about?
NCT02223520 is a clinical study titled "Treating Parents to Reduce NICU Transmission of Staphylococcus Aureus Trial". This trial will test the hypothesis that treating parents of neonates requiring NICU care with intranasal mupirocin and topical chlorhexidine bathing will reduce the spread of S. aureus from parents to neonates.
What is the current status of trial NCT02223520?
This trial is currently completed. It is a NA study. The enrollment target is 307 participants. The study started on 2014-11. Estimated completion is 2019-10-31.
What conditions does trial NCT02223520 study?
This clinical trial studies the following conditions: Staph Aureus Colonization, Staph Aureus Infection.
What interventions are being tested in trial NCT02223520?
The interventions under investigation include: Mupirocin and Chlorhexidine (DRUG), Placebo ointment and placebo cloths (DRUG).
Who is sponsoring clinical trial NCT02223520?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02223520 being conducted?
This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02223520's enrollment target sits among peer trials
307 324th of 2000 higher than 1,677 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05433142 · 307 participants · Phase 1
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
- NCT04162938 · 308 participants · NA
Use of a Patient-Centered Electronic App to Increase ED Patient's Knowledge on HCV to Improve the HCV Care Continuum
- NCT04955795 · 308 participants · NA
Telemedicine for Unhealthy Alcohol Use in Persons Living With HIV Using CETA
- NCT06090539 · 308 participants · Phase 1
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia